Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Jun. 30, 2018
Current assets:    
Cash $ 16,010 $ 15,934
Accounts receivable - trade 119 75
Prepaid expenses and other current assets 206 276
Total Current Assets 16,335 16,285
Fixed assets, net of accumulated depreciation 24,981 25,152
Intangible assets, net of accumulated amortization 1,554 1,620
Security deposit 26 26
Total Assets 42,896 43,083
Current liabilities:    
Accounts payable (related party of $185 and $189 as of September 30, 2018 and June 30, 2018, respectively) 692 790
Accrued expenses (related party of $812 and $789 as of September 30, 2018 and June 30, 2018, respectively) 1,125 1,048
Capital lease obligation – current portion 201 197
Deferred revenue 3,018 0
Total Current Liabilities 5,036 2,035
Capital lease obligation - net of current portion 24,832 24,884
Total Liabilities 29,868 26,919
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized; 18,336,792 and 16,040,126 shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively 18 16
Additional paid-in capital 105,670 104,408
Accumulated other comprehensive loss (31) (30)
Accumulated deficit (92,626) (88,228)
Total iBio, Inc. Stockholders' Equity 13,031 16,166
Noncontrolling interest (3) (2)
Total Equity 13,028 16,164
Total Liabilities and Equity 42,896 43,083
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0